Your Health, We Care
Release date: 2024-12-20 14:08:42 Recommended: 67
Alpelisib is an inhibitor targeting PI3Kα and is mainly used to treat specific types of breast cancer. This article will elaborate on the precautions of the use of apellix, adverse reactions, and the clinical manifestations of adverse skin reactions.
When using apelix, patients and healthcare professionals need to focus on a number of aspects to ensure that it is safe and effective.
The recommended dose of apellix is 300 mg daily (two 150 mg tablets) with food. Patients should take the medication at the same time each day and swallow the tablets whole, avoiding chewing, crushing, or dividing the tablets. If a dose is missed, it should be top-up within 9 hours and skip the dose after 9 hours.
During the use of apellix, patients should regularly monitor blood glucose, liver function, kidney function and other indicators, as well as pay attention to possible adverse reactions such as diarrhea and rash. For patients with serious adverse reactions, the dose should be adjusted or discontinued in time.
Apellix is not indicated for pregnant or lactating women, or people of reproductive potential who are not using contraception. Older adults and patients with renal impairment should use with caution and adjust the dose on a case-by-case basis.
Apellix may cause a series of adverse reactions during treatment, which should be of concern to patients and healthcare professionals.
These include elevated blood glucose, elevated serum creatinine, diarrhea, rash, decreased lymphocyte count, etc. These reactions are common in breast cancer patients and are usually mild to moderate.
Apellix may cause severe hyperglycemia, pneumonia, interstitial lung disease, colitis, etc. These reactions can be life-threatening and require prompt medical attention.
Apellix is embryo-fetal toxic and can cause fetal harm. Therefore, people of reproductive potential should use effective contraception during use.
Apellix can cause serious cutaneous adverse effects, and understanding its clinical manifestations is essential for prompt diagnosis and treatment.
Patients may experience a rash and itching after taking apellix. The rash may appear as erythema, papules, blisters, etc., with varying degrees of itching.
Mucous membranes of the mouth, eyes, genitals and other parts may be affected, such as oral ulcers, conjunctivitis, vaginitis, etc. These lesions may be accompanied by symptoms such as pain and discomfort.
A small number of patients may have severe skin reactions, such as Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), etc. These reactions can be life-threatening and require immediate discontinuation of the drug and medical attention.
Apellix is an effective drug for the treatment of breast cancer, and the precautions, adverse reactions and clinical manifestations of adverse skin reactions during its use should be paid attention to by patients and medical staff. Patients should take their medications exactly as prescribed by their doctor and pay close attention to changes in their symptoms. Health care providers should also strengthen patient monitoring and guidance to ensure the safe and effective use of apellix. Through the joint efforts of both doctors and patients, the therapeutic effect of apellix can be better played and the quality of life of patients can be improved.
